BACKGROUND: Obesity and liver steatosis are both currently attributed to inappropriate lifestyle and nutrition. Higher prevalence of human adenovirus Ad36 seropositivity (Ad36+) is reported only in obesity. AIMS: To investigate whether a lifestyle-nutritional intervention achieves different outcomes in NAFLD patients, i.e., if is blunted or enhanced according to Ad36 seropositivity status. METHODS: One-year nutritional intervention was planned and accomplished for 62 non-alcoholic fatty liver disease overweight-obese patients, studied by liver ultrasound, evaluating Bright Liver Score (BLS), by Homeostatic Model assessment of Insulin Resistance (HOMA), by body composition and Ad36+ assay. Lower salt/lower calories Mediterranean diet, physical activity increase, smoking withdrawal and lifestyle counseling, provided by a health psychologist, were given. RESULTS: Ad36 seropositive patients have baseline greater BMI with the same level of BLS. Different prevalence of post-interventional response, significantly greater among Ad36+ patients, is observed: greater decrease of obesity, assessed by BMI, greater reduction of insulin resistance, assessed by HOMA and higher prevalence of bright liver disappearance. A BMI-adjusted multiple linear regression model explains significantly 23.8% (p < 0.04) of the variance; significant predictive variables are Ad36 seropositivity (p < 0.012) and fat mass loss (p < 0.011) accounting for the variance of the occurrence of bright liver disappearance. CONCLUSIONS: Ad36 previous infection is significantly associated with enhanced weight loss, bright liver disappearance, and recovery of insulin sensitivity through the chosen tailored nutritional interventional treatment. Nonetheless, Ad36 seronegative NAFLD patients' fatty liver pattern improves, at a lower extent, also without significant weight loss: an effect of dietary changes profile, Mediterranean diet, not only of lowered food caloric intake, is conceivably operating.
BACKGROUND:Obesity and liver steatosis are both currently attributed to inappropriate lifestyle and nutrition. Higher prevalence of human adenovirus Ad36 seropositivity (Ad36+) is reported only in obesity. AIMS: To investigate whether a lifestyle-nutritional intervention achieves different outcomes in NAFLDpatients, i.e., if is blunted or enhanced according to Ad36 seropositivity status. METHODS: One-year nutritional intervention was planned and accomplished for 62 non-alcoholic fatty liver disease overweight-obesepatients, studied by liver ultrasound, evaluating Bright Liver Score (BLS), by Homeostatic Model assessment of Insulin Resistance (HOMA), by body composition and Ad36+ assay. Lower salt/lower calories Mediterranean diet, physical activity increase, smoking withdrawal and lifestyle counseling, provided by a health psychologist, were given. RESULTS: Ad36 seropositive patients have baseline greater BMI with the same level of BLS. Different prevalence of post-interventional response, significantly greater among Ad36+ patients, is observed: greater decrease of obesity, assessed by BMI, greater reduction of insulin resistance, assessed by HOMA and higher prevalence of bright liver disappearance. A BMI-adjusted multiple linear regression model explains significantly 23.8% (p < 0.04) of the variance; significant predictive variables are Ad36 seropositivity (p < 0.012) and fat mass loss (p < 0.011) accounting for the variance of the occurrence of bright liver disappearance. CONCLUSIONS: Ad36 previous infection is significantly associated with enhanced weight loss, bright liver disappearance, and recovery of insulin sensitivity through the chosen tailored nutritional interventional treatment. Nonetheless, Ad36 seronegative NAFLDpatients' fatty liver pattern improves, at a lower extent, also without significant weight loss: an effect of dietary changes profile, Mediterranean diet, not only of lowered food caloric intake, is conceivably operating.
Authors: Naga P Chalasani; Arun J Sanyal; Kris V Kowdley; Patricia R Robuck; Jay Hoofnagle; David E Kleiner; Aynur Unalp; James Tonascia Journal: Contemp Clin Trials Date: 2008-09-10 Impact factor: 2.226
Authors: Hui-Hui Tan; M Isabel Fiel; Qinghua Sun; Jinsheng Guo; Ronald E Gordon; Lung-Chi Chen; Scott L Friedman; Joseph A Odin; Jorge Allina Journal: J Immunotoxicol Date: 2009-12 Impact factor: 3.000
Authors: Maya Gambarin-Gelwan; Sanjiv V Kinkhabwala; Thomas D Schiano; Carol Bodian; Hsu-Chong Yeh; Walter Futterweit Journal: Clin Gastroenterol Hepatol Date: 2007-02-06 Impact factor: 11.382
Authors: John P Kirwan; Thomas P J Solomon; Daniel M Wojta; Myrlene A Staten; John O Holloszy Journal: Am J Physiol Endocrinol Metab Date: 2009-04-21 Impact factor: 4.310
Authors: D Enette Larson-Meyer; Bradley R Newcomer; Leonie K Heilbronn; Julia Volaufova; Steven R Smith; Anthony J Alfonso; Michael Lefevre; Jennifer C Rood; Donald A Williamson; Eric Ravussin Journal: Obesity (Silver Spring) Date: 2008-04-10 Impact factor: 5.002
Authors: Nathan A Johnson; Toos Sachinwalla; David W Walton; Kate Smith; Ashley Armstrong; Martin W Thompson; Jacob George Journal: Hepatology Date: 2009-10 Impact factor: 17.425
Authors: Cynthia L Chappell; Mary Dickerson; R Sue Day; Olga Dubuisson; Nikhil V Dhurandhar Journal: J Virol Methods Date: 2016-11-05 Impact factor: 2.014
Authors: Emma M Laing; Ralph A Tripp; Norman K Pollock; Clifton A Baile; Mary Anne Della-Fera; Srujana Rayalam; Stephen M Tompkins; Deborah A Keys; Richard D Lewis Journal: J Bone Miner Res Date: 2013-03 Impact factor: 6.741
Authors: Francesca M Trovato; Daniela Catalano; Adriana Garozzo; G Fabio Martines; Clara Pirri; Guglielmo M Trovato Journal: World J Gastroenterol Date: 2014-10-28 Impact factor: 5.742
Authors: H Zamrazilová; I Aldhoon-Hainerová; R L Atkinson; L Dušátková; B Sedláčková; Z P Lee; M Kunešová; M Hill; V Hainer Journal: Int J Obes (Lond) Date: 2015-08-25 Impact factor: 5.095
Authors: I Aldhoon-Hainerová; H Zamrazilová; R L Atkinson; L Dušátková; B Sedláčková; P Hlavatý; Z P Lee; M Kunešová; V Hainer Journal: Int J Obes (Lond) Date: 2013-05-14 Impact factor: 5.095